Junten Bio is a pioneering biotechnology company focused on the research and development of advanced cell therapies and diagnostic agents. The company primarily serves the healthcare sector, targeting medical institutions and research organizations involved in organ transplants. Operating in the biotechnology market, Junten Bio's business model revolves around developing and licensing novel cell therapies and antibody drugs designed to improve the success rates of organ transplants, including liver and kidney transplants. The company generates revenue through licensing agreements and partnerships with other pharmaceutical firms, such as its recent collaborations with AlliedCel Corporation and Sysmex Corporation. By leveraging cutting-edge research and strategic alliances, Junten Bio aims to contribute significantly to the global healthcare industry.

Keywords: cell therapy, diagnostic agents, organ transplants, biotechnology, healthcare, liver transplants, kidney transplants, licensing agreements, antibody drugs, medical research.